Daiichi Sankyo UK Ltd.

Grants

Update: Since January 2022, DSUK has been working with NHS England on a programme around optimising AF-related stroke prevention (Detect, Protect, Perfect). As of the 11th of March 2024, DSUK are unable to accept any new Grants applications under this category. For any submitted applications, DSUK and NHS England will evaluate all remaining funding requests and respond in due course. 

What is a Grant?

The term Grants applies to the provision of funding for actual goods and services given for the purpose of supporting healthcare, scientific research, or education. This is in response to an unsolicited request from a healthcare organisation, or those involved with the provision of healthcare, and must be provided without any implied or actual benefit in return for Daiichi Sankyo UK.

Grants to individuals are prohibited.

What types of Grant will Daiichi Sankyo consider supporting?

Daiichi Sankyo UK are committed to supporting projects, initiatives, and concepts which enhance patient care or benefit the NHS and maintain sustainable, high-quality care for patients.

This could include, but is not limited to:

  • Funding for innovative care models which drive efficiency and quality, within the oncology and cardiovascular disease therapy areas
  • Support with clinical education and upskilling of the clinical workforce above that which is part of the standard training
  • Projects and initiatives which seek to address a population health need, disease burden, or reduction in unplanned hospital admissions
  • Provision of funding to patient groups or charitable organisations which aim to improve awareness amongst clinicians, patients, and the general public, within the oncology and cardiovascular disease therapy areas

All grants are provided on the basis of application merit and are not allocated on the basis of any perceived or expected financial material benefit to the Daiichi Sankyo UK organisation. All grants are considered on a first-come-first-serve basis and allocation of funding may be influenced by availability of budgets at the time of the application.

What are the criteria used to determine which grants are funded?

Daiichi Sankyo UK receives many requests for funding and may not be able to support all applications. Whilst all requests are considered, each request may not be successful.

Approval of funding requests are at the discretion of Daiichi Sankyo UK and requests for funding will be prioritised in our focus disease areas:

  • CVD prevention and management (which includes lipid management and AF)
  • General Adult Oncology (which includes Breast, Lung and Gastric cancers)

Daiichi Sankyo UK Ltd considers the following factors when evaluating which activities to support.

  • Does it support healthcare, scientific research, or education?
  • Does the project, initiative, or concept enhance patient care beyond that provided in routine practice within the NHS?
  • Does the application represent an innovative approach to patient care, which is demonstrably outside of existing contracted NHS services (as far as can be determined)?
  • Does the application benefit and enable the NHS to improve care for patients, aim to reduce health inequalities, and is there a legacy associated with the project that will improve care provision over a longer term?
  • Does it meet the UK regulatory requirements of the Association of British Pharmaceutical Industry (ABPI) and Medicines and Healthcare products Regulatory Agency (MHRA)?

Please note that applications are not guaranteed even if all criteria are met.

If support is provided through a grant this must be acknowledged and apparent on any materials associated with the activity e.g., educational items or materials used. In line with the requirements of the ABPI Code of Practice for the Pharmaceutical Industry, details of grant funding provided by Daiichi Sankyo UK will be publicly disclosed annually on the ABPI central website platform for disclosure in the UK.

Disclosure and compliance

As a UK-based pharmaceutical company, Daiichi Sankyo UK adheres to the ABPI Code of Practice, including the requirements for annual disclosure of transfer of value for the corresponding period.

Details of each grant (transfer of value) must be publicly disclosed annually, giving in each case the financial amount or value and the name of the recipient institution, organisation, or association. Companies are also encouraged to ask recipients to make such funding public. Where applicable, fees and expenses should be disclosed separately. Disclosure must be carried out in accordance with Clauses 28 and 29. Further information on public disclosures of transfer value from Daiichi Sankyo UK can be found on the Disclosure UK portal: https://search.disclosureuk.org.uk/

Application process

To apply for a grant from Daiichi Sankyo UK please download and complete the appropriate form and the anti-bribery questionnaire Please note both fully completed forms are required in order for an application to be accepted and processed. 

Please do not use the below forms to report adverse events.

For activities not covered by a DSUK Grant, please see the Q&A document below.

The relevant application forms are available below

Once completed, please email the forms to Grantsanddonations@daiichi-sankyo.co.uk

 

Adverse Event Reporting 

Side effects (adverse events) should be reported. The documents for some medicines also display an inverted black triangle symbol indicating that they are subject to additional monitoring to support the quick identification of new safety information.

If you are a patient and experience any side effects while taking a Daiichi Sankyo product, please talk to your doctor, pharmacist, or nurse. You can also report side effects directly to the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.  By reporting side effects, you can help build the knowledge regarding the safety of the medicine.

If you are a health professional, adverse event reporting forms and information can be found at www.mhra.gov.uk/yellowcard (or search for MHRA Yellow Card in Google Play or Apple App store). Adverse events should also be reported to Daiichi Sankyo on 0800 028 5122 or by email to pharmacovigilance@daiichi-sankyo.co.uk

 

UK/DSC/03/24/0001 March 2024

back to top